Category Filter
Policies & Guidelines
- Advanced Imaging
- Autism Spectrum Mandate
- Behavioral Health
- Blue Advantage Policies
- Chronic Condition Management
- Genetic Testing
- HelpScript Program
- Hemophilia Drugs
- Medical Oncology Regimen Program
- Medical Policies
- Pharmacy
- Pre-Service Review (Precertification and Predetermination)
- Pre-Service Review (Precertification/Predetermination)
- Pre-Service Review (Predetermination/Precertification)
- Provider-Administered Drug Policies
- Radiation Therapy
- Self-Administered Drug Policies
- Transgender Services
Asset Publisher
Content with Policies & Guidelines Final Self-Administered Drug Policies .
print
Print
Back
Back
Keveyis Prior Authorization with Quantity Limit Program Summary
Policy Number: PH-1053
...
Aubagio®, Avonex®, Bafiertam®, Betaseron®, Copaxone® Extavia®, Gilenya®, Glatopa®, Kesimpta®, Mavenclad®, Mayzent®, Plegridy®, Rebif®,&nb...
Adcirca, Adempas, Letairis, Liqrev, Opsumit, Orenitram, Revatio, Tadliq, Tracleer, Tyvaso, Tyvaso DPI, Uptravi, Ventavis
Acticlate, Doxycycline monohydrate, Doryx, Doryx MPC, doxycycline hyclate, Monodox, Oracea, Vibramycin, Minocin, Minocycline ER capsule, Minocycline ER tablet, Minolira, Solodyn, Ximino, Seysara,...